Hironaka, Shuichi http://orcid.org/0000-0001-9714-231X
Komori, Azusa
Machida, Ryunosuke
Ito, Yoshinori
Takeuchi, Hiroya
Ogawa, Gakuto
Kato, Ken
Onozawa, Masakatsu
Minashi, Keiko
Yano, Tomonori
Nakamura, Kenichi
Tsushima, Takahiro
Hara, Hiroki
Nozaki, Isao
Ura, Takashi
Chin, Keisho
Fukuda, Haruhiko
Kitagawa, Yuko
Funding for this research was provided by:
Grant-in-Aid for Cancer Research (20-S-3, 23-A-19, 26-A-4, 29-S-3)
National Cancer Center Research and Development Fund (23-A-16, 23-A-19, 26-A-4, 29-A-3)
Article History
Received: 20 January 2020
Accepted: 21 April 2020
First Online: 28 April 2020
Compliance with ethical standards
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Informed consent or substitute for it was obtained from all patients for being included in the study.
: Dr. Hironaka reports personal fees from Tsumura & Co., Bristol-Myers Squibb Japan, Yakult Honsha, Daiichi Sankyo, Eli Lilly, Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharma, Nihonkayaku, outside the submitted work; Dr. Machida reports grants from Ministry of Health, Labour and Welfare, Japan, during the conduct of the study; Dr. Ogawa reports grants from Ministry of Health, Labour and Welfare, Japan, grants from Japan Agency for Medical Research and Development (AMED), during the conduct of the study; Dr. Kato reports other from Ono Pharmaceuticals, personal fees from BMS, Eli Lilly, other from MSD, Shionogi, Beigene, Oncolys BioPharma, Merck Biopharma, outside the submitted work; Dr. Nakamura reports personal fees from Chugai, Taiho, Bayer, outside the submitted work; Dr. Hara reports grants from Japan Agency for Medical Research and Development (AMED), during the conduct of the study; grants from Astrazeneca, Dainippon Sumitomo Pharma, Merck Biopharma, Eisai, LSK BioPharma, Incyte, Pfizer, Boehringer-ingelheim, Beigene, grants and personal fees from Daiichi Sankyo, MSD, Taiho, Chugai, Ono, BMS, personal fees from Lilly, Yakult Honsha, Sanofi, Takeda, Astellas, outside the submitted work; Dr. Nakamura reports personal fees from Chugai, personal fees from Taiho, personal fees from Bayer, outside the submitted work; Dr. Fukuda reports grants from National Cancer Center and the Ministry of Health, Labour and Welfare of Japan, during the conduct of the study; personal fees from Taiho Pharma, personal fees from Chugai Pharmaceutical, outside the submitted work; Dr. Kitagawa reports grants from Pfizer Japan Inc., Yakult Honsha Co. Ltd., Kyowa Hakko Kirin Co., Ltd., during the conduct of the study; grants from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Daiichi Sankyo Company Ltd., Merck Serono Co., Ltd., Asahi Kasei Co., Ltd., EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd., Kaken Pharmaceutical Co., Ltd, Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Pfizer Japan Inc., ONO Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., Japan Blood Products Organization, Medtronic Japan Co., Ltd., Sanofi K.K., Eisai Co., Ltd., Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., outside the submitted work; Dr. Komori, Dr. Ito, Dr. Takeuchi, Dr. Onozawa, Dr. Minashi, Dr. Yano, Dr. Tsushima, Dr. Nozaki, Dr. Ura, and Dr. Chin has nothing to disclose.